Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2018 Sep 1;22(9):983-990. doi: 10.5588/ijtld.17.0859.

Measuring catastrophic costs due to tuberculosis in Viet Nam.

Author information

1
National Tuberculosis Programme Viet Nam, Hanoi, Viet Nam Association for Tuberculosis and Lung Disease, Hanoi, Viet Nam.
2
National Tuberculosis Programme Viet Nam, Hanoi, Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, Paris, France.
3
Hanoi Medical University, Hanoi, Viet Nam.
4
National Tuberculosis Programme Viet Nam, Hanoi.
5
World Health Organization, Global Tuberculosis Programme, Geneva, Switzerland.
6
Department of Public Health Sciences, the Karolinska Institute, Stockholm, Sweden.

Abstract

INTRODUCTION:

Progress towards ending tuberculosis (TB) in Viet Nam includes monitoring the costs borne by patients through periodic facility-based surveys.

OBJECTIVE:

To document the magnitude of costs incurred by TB-affected households and establish a baseline for the top End TB indicator in Viet Nam.

METHODS:

A national survey with retrospective data collection and projection among 735 participants in 20 stratified clusters was conducted in 2016. Each patient was interviewed on costs, time loss, coping measures and asset ownership. Total costs were expressed as a proportion of annual household income.

RESULTS:

In Viet Nam, 63% of households affected by TB or multidrug-resistant TB (MDR-TB) experienced costs that were >20% of their annual household income. The mean patient costs were respectively US$1054 and US$4302 per episode of TB and MDR-TB. The most significant drivers of mean costs were income loss reported and purchase of special foods, nutritional supplements, travel and accommodation.

CONCLUSION:

The proportion of households experiencing catastrophic total costs due to TB in Viet Nam is high, which poses a barrier to TB diagnosis and treatment. Based on study results, programme and partners need to identify key areas for policy action and work towards a national policy guide on intervention to reduce TB patient costs.

Comment in

PMID:
30092862
DOI:
10.5588/ijtld.17.0859
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center